Abstract
Glutamate carboxypeptidase II (GCPII) and its splice variants, paralogs and human homologs represent a family of proteins with diverse tissue distribution, cellular localization and largely unknown function which have been explored only recently. While GCPII itself has been thoroughly studied from different perspectives, as clearly documented in this series of reviews, very little is known about other members of its family, even though they might be biologically relevant. Differential expression of individual GCPII splice variants is associated with tumor progression and prognosis of prostate cancer. The best studied GCPII homolog, GCPIII or NAALADase II, may be a valid pharmaceutical target for itself since it may compensate for a lack of normal GCPII enzymatic activity. Detailed molecular characterization of this family of proteins is thus very important not only with respect to the potential therapeutic use of GCPII inhibitors, but also for better understanding of the biological role of GCPII within as well as outside the nervous system.
Keywords: PSMA, GCPIII, NAALADase L, PSMAL, Splice variants, Homologs, Glutamate carboxypeptidase II (GCPII), biological role, cancer metastasis
Current Medicinal Chemistry
Title: GCPII Variants, Paralogs and Orthologs
Volume: 19 Issue: 9
Author(s): K. Hlouchova, V. Navratil, J. Tykvart, P. Sacha and J. Konvalinka
Affiliation:
Keywords: PSMA, GCPIII, NAALADase L, PSMAL, Splice variants, Homologs, Glutamate carboxypeptidase II (GCPII), biological role, cancer metastasis
Abstract: Glutamate carboxypeptidase II (GCPII) and its splice variants, paralogs and human homologs represent a family of proteins with diverse tissue distribution, cellular localization and largely unknown function which have been explored only recently. While GCPII itself has been thoroughly studied from different perspectives, as clearly documented in this series of reviews, very little is known about other members of its family, even though they might be biologically relevant. Differential expression of individual GCPII splice variants is associated with tumor progression and prognosis of prostate cancer. The best studied GCPII homolog, GCPIII or NAALADase II, may be a valid pharmaceutical target for itself since it may compensate for a lack of normal GCPII enzymatic activity. Detailed molecular characterization of this family of proteins is thus very important not only with respect to the potential therapeutic use of GCPII inhibitors, but also for better understanding of the biological role of GCPII within as well as outside the nervous system.
Export Options
About this article
Cite this article as:
Hlouchova K., Navratil V., Tykvart J., Sacha P. and Konvalinka J., GCPII Variants, Paralogs and Orthologs, Current Medicinal Chemistry 2012; 19 (9) . https://dx.doi.org/10.2174/092986712799462676
DOI https://dx.doi.org/10.2174/092986712799462676 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Estrogens and Thyroid Hormones: Non-Genomic Effects are Coupled to Transcription
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Density Functional Theory, Docking, Bioisosteric Replacement, Pharmacophore Perception, Physical Chemical Analyses of the Interactions of Novel PIM-1 Inhibitors with Suitable Pharmacokinetic Properties for Cancer Treatment
Current Physical Chemistry The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets Subject Index to Volume 3
Current Medicinal Chemistry - Central Nervous System Agents Toxicology of Tributyltin in Mammalian Animal Models
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Liposomal-All-trans-Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia
Current Cancer Therapy Reviews Potential Interactions of Carotenoids with Other Bioactive Food Components in the Prevention of Chronic Diseases
Current Bioactive Compounds Nebulizer Therapy in Pulmonology: Review of the Literature
Current Respiratory Medicine Reviews Natural Products As Antimitotic Agents
Current Topics in Medicinal Chemistry Peripheral TRPV1 Receptors As Targets for Drug Development: New Molecules and Mechanisms
Current Pharmaceutical Design Antisense Technology: A Selective Tool for Gene Expression Regulation and Gene Targeting
Current Pharmaceutical Biotechnology Application in Electrochemistry of Graphene-Modified Electrodes
Micro and Nanosystems Editorial [Hot Topic:Fluorine-Containing Drugs as PET Diagnostics (F-18 Labeled Tracers)]
Current Topics in Medicinal Chemistry Treatment of PSA only Recurrence of Prostate Cancer After Prior Local Therapy
Current Pharmaceutical Design Therapeutic Application of Natural Medicine Monomers in Cancer Treatment
Current Medicinal Chemistry Suppression of NF-κB Signaling and P-glycoprotein Function by Gambogic Acid Synergistically Potentiates Adriamycin -induced Apoptosis in Lung Cancer
Current Cancer Drug Targets What is Currently the Best Radiopharmaceutical for the Hybrid PET/CT Detection of Recurrent Medullary Thyroid Carcinoma?
Current Radiopharmaceuticals Recent Advances in Diagnostic and Therapeutic Approaches for Breast Cancer: A Comprehensive Review
Current Pharmaceutical Design The Interplay Between Inflammation and Oxidative Stress in Carcinogenesis
Current Molecular Medicine